表紙
市場調査レポート

Intellect Neurosciences, Inc.:製品パイプライン分析

Intellect Neurosciences, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 259396
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Intellect Neurosciences, Inc.:製品パイプライン分析 Intellect Neurosciences, Inc. - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 30 Pages
概要

Intellect Neurosciences, Inc.は、アルツハイマー病およびその他の重篤な神経疾患の治療薬や予防薬を開発するバイオ医薬品企業です。

当レポートでは、Intellect Neurosciences, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Intellect Neurosciences, Inc.の基本情報

Intellect Neurosciences, Inc.の概要

  • 主要情報
  • 企業情報

Intellect Neurosciences, Inc.:R&Dの概要

  • 主な治療範囲

Intellect Neurosciences, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Intellect Neurosciences, Inc.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Intellect Neurosciences, Inc.:薬剤プロファイル

  • INN-01
  • INN01-OX2
  • RV-01
  • RV-02
  • RV-03
  • TauC3モノクローナル抗体
  • T-01OX2
  • TOC-1

Intellect Neurosciences, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Intellect Neurosciences, Inc.:最近のパイプライン動向

Intellect Neurosciences, Inc.:休止中のプロジェクト

Intellect Neurosciences, Inc.:企業発表

Intellect Neurosciences, Inc.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07710CDB

Summary

Global Markets Direct's, 'Intellect Neurosciences, Inc. - Product Pipeline Review - 2015', provides an overview of the Intellect Neurosciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Intellect Neurosciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Intellect Neurosciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Intellect Neurosciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Intellect Neurosciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate Intellect Neurosciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Intellect Neurosciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Intellect Neurosciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Intellect Neurosciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Intellect Neurosciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Intellect Neurosciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Intellect Neurosciences, Inc. Snapshot
    • Intellect Neurosciences, Inc. Overview
    • Key Information
    • Key Facts
  • Intellect Neurosciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Intellect Neurosciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Intellect Neurosciences, Inc. - Pipeline Products Glance
    • Intellect Neurosciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Intellect Neurosciences, Inc. - Drug Profiles
    • INN-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INN01-OX2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RV-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RV-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RV-03
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TauC-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TOC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Intellect Neurosciences, Inc. - Pipeline Analysis
    • Intellect Neurosciences, Inc. - Pipeline Products by Target
    • Intellect Neurosciences, Inc. - Pipeline Products by Route of Administration
    • Intellect Neurosciences, Inc. - Pipeline Products by Molecule Type
    • Intellect Neurosciences, Inc. - Pipeline Products by Mechanism of Action
  • Intellect Neurosciences, Inc. - Recent Pipeline Updates
  • Intellect Neurosciences, Inc. - Dormant Projects
  • Intellect Neurosciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Intellect Neurosciences, Inc., Key Information
  • Intellect Neurosciences, Inc., Key Facts
  • Intellect Neurosciences, Inc. - Pipeline by Indication, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Stage of Development, 2015
  • Intellect Neurosciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Intellect Neurosciences, Inc. - Out-Licensed Products in Pipeline, 2015
  • Intellect Neurosciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Intellect Neurosciences, Inc. - Preclinical, 2015
  • Intellect Neurosciences, Inc. - Discovery, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Target, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Route of Administration, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Molecule Type, 2015
  • Intellect Neurosciences, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Intellect Neurosciences, Inc. - Recent Pipeline Updates, 2015
  • Intellect Neurosciences, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Intellect Neurosciences, Inc. - Pipeline by Top 10 Indication, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Stage of Development, 2015
  • Intellect Neurosciences, Inc. - Monotherapy Products in Pipeline, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Top 10 Target, 2015
  • Intellect Neurosciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Intellect Neurosciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top